Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$39.26 USD

39.26
1,211,621

+0.45 (1.16%)

Updated Nov 1, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Amgen's (AMGN) Q1 Earnings Top, Stock Down on IRS Tax Dispute

by Zacks Equity Research

Amgen (AMGN) beats Q1 estimates for earnings and sales. The stock declines on the announcement of litigation and tax dispute with the IRS.

Will Biogen (BIIB) Succeed in Beating Q1 Earnings Estimates?

by Zacks Equity Research

Biogen's (BIIB) multiple sclerosis revenues have been declining since the past few quarters. It is unlikely that MS sales have improved in the first quarter.

Novartis (NVS) Beats on Q1 Earnings, Sandoz Posts Growth

by Zacks Equity Research

Novartis (NVS) beats on earnings in the first quarter but sales lag expectations. Generic Sandoz business returns to growth.

Is a Beat Likely for AbbVie (ABBV) This Earnings Season?

by Zacks Equity Research

AbbVie's (ABBV) first-quarter results are expected to reflect the impact of strong demand for immunology drugs, aesthetics and cosmetics products. Investors are likely to focus on any update related to Humira LOE.

Roche's (RHHBY) Q1 Sales Grow on COVID-19 Tests, New Drugs

by Zacks Equity Research

Roche (RHHBY) performance in the first quarter was encouraging, driven by demand for COVID-19 tests and contribution from newer drugs.

Halzoyme (HALO) Up 8.3% YTD: Will It Continue to Trend Higher?

by Zacks Equity Research

Halozyme's (HALO) revenues are driven by strong demand for new partnered drugs. Restructuring initiatives are boosting margins. Robust revenue growth is expected to continue in 2022.

    The Zacks Analyst Blog Highlights Johnson & Johnson, Roche Holding, Raytheon Technologies, Intuit and Target

    by Zacks Equity Research

    Johnson & Johnson, Roche Holding, Raytheon Technologies, Intuit and Target have been included in this Analyst Blog.

    Sheraz Mian headshot

    Top Research Reports for Johnson & Johnson, Roche & Raytheon

    by Sheraz Mian

    Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Roche Holding AG (RHHBY), and Raytheon Technologies Corporation (RTX).

    Prothena (PRTA) Stock Gains 51% in a Year: What Lies Ahead?

    by Zacks Equity Research

    Prothena (PRTA) has had a phenomenal run in the past year, primarily due to its promising pipeline for AD.

    Kinjel Shah headshot

    Pharma Stock Roundup: PFE to Buy RSV Drugmaker, FDA Updates for NVS, MRK and RHHBY

    by Kinjel Shah

    Pfizer (PFE) announces plans to acquire ReViral for up to $525 million. Merck (MRK), Novartis (NVS) and Roche (RHHBY) provide FDA updates.

    Biogen (BIIB) Down as Medicare Limits Coverage for Aduhelm

    by Zacks Equity Research

    Biogen (BIIB) stock declines after Medicare limits coverage for FDA-approved Alzheimer's drugs like Aduhelm only for patients enrolled in CMS-approved studies.

    Regeneron (REGN), Sanofi's Dupixent Gets EU Nod for Asthma in Kids

    by Zacks Equity Research

    Regeneron (REGN) and Sanofi's (SNY) Dupixent receives label expansion in the European Union for severe asthma with type 2 inflammation in children aged between 6 years and 11 years.

    Halozyme's (HALO) ENHANZE Drives Sales Amid Rising Competition

    by Zacks Equity Research

    Halozyme (HALO) is attracting partnerships from several large pharma companies as well as biotechs, courtesy of its ENHANZE technology. Royalties and product supply to partners are likely to drive revenues.

    Roche (RHHBY) Actemra Application Receives Priority Review

    by Zacks Equity Research

    Roche (RHHBY) sBLA is seeking approval for the intravenous formulation of arthritis drug Actemra accepted and granted Priority Review in the United States.

    Kinjel Shah headshot

    Pharma Stock Roundup: FDA Nod for 2nd COVID Booster, New Approvals for AZN, GSK, NVS

    by Kinjel Shah

    FDA authorizes second booster dose of PFE and MRNA COVID-19 vaccines for older adults. RHHBY's late-stage study for ES-SCLC fails.

    Biogen (BIIB) Plans to Start Aduhelm Confirmatory Study in May

    by Zacks Equity Research

    Biogen (BIIB) expects to start the phase IV post-marketing confirmatory study of Aduhelm for Alzheimer's disease in May 2022. The estimated completion period of the study is four years.

    ImmunoGen (IMGN) Files BLA for Lead Drug in Ovarian Cancer

    by Zacks Equity Research

    ImmunoGen (IMGN) seeks accelerated approval from the FDA for its lead candidate, mirvetuximab soravtansine, in previously treated platinum-resistant ovarian cancer. This pushes the stock price up.

    Roche (RHHBY) Late-Stage Study for ES-SCLC Fails to Meet Goal

    by Zacks Equity Research

    Roche (RHHBY) phase III SKYSCRAPER-02 study assessing tiragolumab plus Tecentriq and chemotherapy as a first-line treatment for extensive-stage small cell lung cancer did not meet co-primary endpoint of progression-free survival.

    JAZZ Initiates Zepzelca Basket Study in Advanced Solid Tumors

    by Zacks Equity Research

    JAZZ enrolls the first patient in a mid-stage study to evaluate its lung cancer drug, Zepzelca, in advanced and difficult-to-treat cancer indications in previously-treated patients.

    Halozyme (HALO) Inks Collaboration Deal With Chugai Pharma

    by Zacks Equity Research

    Halozyme (HALO) and Japan-based Chugai Pharma sign a collaboration agreement, which gives the latter an exclusive right to Halozyme's ENHANZE technology to develop a therapy for an undisclosed target.

    Amgen (AMGN) Outperforms Industry This Year So Far: What Next?

    by Zacks Equity Research

    Amgen's (AMGN) key drugs like Prolia, Repatha, Xgeva and biosimilars are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.

    Epizyme (EPZM) Down More Than 50% in Past 3 Months: Here's Why

    by Zacks Equity Research

    Epizyme's (EPZM) lead drug, Tazverik, is approved to treat follicular lymphoma and epithelioid sarcoma in the United States. Stiff competition in the target remains an overhang.

    Seagen's (SGEN) Cancer Drugs Aid Growth, Stiff Rivalry a Woe

    by Zacks Equity Research

    Seagen (SGEN) focuses on improving sales of its marketed drugs that are approved for different types of cancer indications. Stiff competition in the target market remains a woe.

    Exelixis (EXEL) Announces Final Results From HCC Study

    by Zacks Equity Research

    Exelixis (EXEL) does not intend to submit a supplemental new drug application to the FDA for Cabometyx in patients with previously untreated advanced hepatocellular carcinoma.

    AbbVie (ABBV) Inks Deal for Neuropsychiatric Conditions

    by Zacks Equity Research

    AbbVie (ABBV) forges an alliance with Gedeon Richter to develop novel treatments for neuropsychiatric diseases. Both collaborated in the past too on the blockbuster schizophrenia drug Vraylar.